Unknown

Dataset Information

0

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.


ABSTRACT: Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199. This sensitivity occurs in part through low anti-apoptotic BCL-xL expression, high pro-apoptotic NOXA expression, and paradoxical, MYCN-driven upregulation of NOXA. Screening for enhancers of ABT-199 sensitivity in MYCN-amplified neuroblastomas, we demonstrate that the Aurora Kinase A inhibitor MLN8237 combines with ABT-199 to induce widespread apoptosis. In diverse models of MYCN-amplified neuroblastoma, including a patient-derived xenograft model, this combination uniformly induced tumor shrinkage, and in multiple instances led to complete tumor regression.

SUBMITTER: Ham J 

PROVIDER: S-EPMC4749542 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham Jungoh J   Costa Carlotta C   Sano Renata R   Lochmann Timothy L TL   Sennott Erin M EM   Patel Neha U NU   Dastur Anahita A   Gomez-Caraballo Maria M   Krytska Kateryna K   Hata Aaron N AN   Floros Konstantinos V KV   Hughes Mark T MT   Jakubik Charles T CT   Heisey Daniel A R DA   Ferrell Justin T JT   Bristol Molly L ML   March Ryan J RJ   Yates Craig C   Hicks Mark A MA   Nakajima Wataru W   Gowda Madhu M   Windle Brad E BE   Dozmorov Mikhail G MG   Garnett Mathew J MJ   McDermott Ultan U   Harada Hisashi H   Taylor Shirley M SM   Morgan Iain M IM   Benes Cyril H CH   Engelman Jeffrey A JA   Mossé Yael P YP   Faber Anthony C AC  

Cancer cell 20160201 2


Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199. This sensitivity occurs in part through low anti-apoptotic BCL-xL expression, high pro-apoptotic NOXA expression, and paradoxical, MYCN-driven upregulation of NOXA.  ...[more]

Similar Datasets

| S-EPMC7321810 | biostudies-literature
| S-EPMC3503288 | biostudies-literature
| S-EPMC7502401 | biostudies-literature
| S-EPMC8020796 | biostudies-literature
| S-EPMC8819351 | biostudies-literature
| S-EPMC6279278 | biostudies-literature
| S-EPMC10707345 | biostudies-literature
| S-EPMC5945521 | biostudies-literature
| S-EPMC2749594 | biostudies-literature
| S-EPMC4664780 | biostudies-literature